News

ASCO 2015: Dr. Hope S. Rugo gives her top picks in breast cancer research


 

References

Dr. Hope S. Rugo picks the upcoming ASCO presentations she anticipates to be the most interesting in breast cancer research.

Dr. Hope S. Rugo

Dr. Hope S. Rugo

1004 Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.

1018 Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer.

507 Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.

LBA502 PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone-receptor positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.

1001 Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.

501 Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance).

9518 Clinical performance of the DigniCap system, a scalp hypothermia system, in preventing chemotherapy-induced alopecia.

LBA500 Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.

504 Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.

508 Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase III, randomized, placebo-controlled trial (ExteNET).

Dr. Rugo is a professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.

Recommended Reading

ASA: Radiation lowers local recurrence risk for DCIS patients with close or positive margins
MDedge Hematology and Oncology
Cardiac monitoring falls short in elderly breast cancer patients given trastuzumab
MDedge Hematology and Oncology
Low-risk luminal A breast cancers may not require radiation Tx
MDedge Hematology and Oncology
Similar 5-year outcomes from accelerated partial-breast irradiation, whole-breast irradiation
MDedge Hematology and Oncology
Neoadjuvant chemotherapy for triple negative breast cancer improves conservation
MDedge Hematology and Oncology
Treatment of metastatic breast cancer with nab-paclitaxel in the community practice setting: a US oncology survey
MDedge Hematology and Oncology
Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result
MDedge Hematology and Oncology
A quarter of women with dense breasts at high interval cancer risk
MDedge Hematology and Oncology
ACOG spells out risk assessment for hereditary cancer syndromes
MDedge Hematology and Oncology
ASCO 2015: Dr. William J. Gradishar gives his top picks in breast cancer research
MDedge Hematology and Oncology